LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
暂无分享，去创建一个
E. Raymond | L. Wyrwicz | J. Shi | A. Tao | J. Zhang | T. Kojima | R. Hubner | Y. Jiang | K. Kato | L. Wang | E. Gotovkin | C. Lin | L. Li | Y. Pan | R. Ishihara | Y. Shu | H. Yoon | S. Park | J. Xu